StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Zyprexa (olanzapine) by Quarter

Zyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

QuarterlyAnnual

Eli Lilly Zyprexa (olanzapine): $8.80M in Q4 2024, down 79.9% from a year earlier. That is the lowest of the 28 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
8.80
Period ended Dec 31, 2024
Change on a year earlier
-79.9%
43.8 in Q4 2023
History
28 quarters
Since Q1 2017
Sources
25
Documents cited below

Where the Q4 2024 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K FY2024 (filed 2025-02-19) ↗

Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
Q4 2024Dec 31, 20248.80-79.9%Form 10-K FY2024 (filed 2025-02-19) ↗
Q3 2024Sep 30, 202431.7-97.9%Form 10-Q (filed 2024-10-30) ↗
Q4 2023Dec 31, 202343.8-41.8%Form 10-K FY2023 (filed 2024-02-21) ↗
Q3 2023Sep 30, 20231,481+1,719.9%Form 10-Q (filed 2024-10-30) ↗
Q4 2022Dec 31, 202275.2-45.3%Form 10-K FY2022 (filed 2023-02-22) ↗
Q3 2022Sep 30, 202281.4-20.0%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 202287.3-8.5%Form 10-Q (filed 2022-08-04) ↗
Q1 2022Mar 31, 202293.1-2.8%Form 10-Q (filed 2022-04-29) ↗
Q4 2021Dec 31, 2021138+39.2%Form 10-K FY2021 (filed 2022-02-23) ↗
Q3 2021Sep 30, 2021102-9.8%Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 202195.4-1.2%Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 202195.8-2.6%Form 10-Q (filed 2022-04-29) ↗
Q4 2020Dec 31, 202098.8-36.0%Form 10-K FY2020 (filed 2021-02-17) ↗
Q3 2020Sep 30, 2020113+6.9%Form 10-Q (filed 2021-10-27) ↗
Q2 2020Jun 30, 202096.6-7.4%Form 10-Q (filed 2021-08-03) ↗
Q1 2020Mar 31, 202098.4-8.2%Form 10-Q (filed 2021-04-30) ↗

Breakdown

What makes up zyprexa (olanzapine)

Cite this data

StockData. (2026). Eli Lilly Zyprexa (olanzapine) ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zyprexa-ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.